Welcome to our dedicated page for 10X Genomics news (Ticker: TXG), a resource for investors and traders seeking the latest updates and insights on 10X Genomics stock.
10x Genomics, Inc. (NASDAQ: TXG) is a life science technology company focused on single cell and spatial biology, and this news page aggregates company-related announcements, research collaborations and financial updates. The company’s integrated research solutions include instruments, consumables and software that are used by academic and translational researchers and biopharmaceutical companies to study complex biological systems.
News about 10x Genomics often highlights developments in its technology platforms, such as new single cell instruments, assays and spatial workflows. Recent announcements have described launches and enhancements within the Chromium single cell portfolio, including instruments and assays designed to make high-performance single cell analysis more accessible and scalable. The company has also reported new capabilities on its Xenium spatial platform, including spatial multiomic workflows that enable simultaneous RNA and protein detection on tissue sections.
Another key theme in TXG news is large-scale research collaborations. 10x Genomics has announced partnerships with academic medical centers, cancer institutes, research consortia and nonprofit organizations to apply its single cell and spatial technologies in areas such as autoimmune disease, oncology, immuno-oncology and transplantation. These initiatives often involve generating high-resolution molecular maps of cells and tissues, linking them with clinical data and exploring potential diagnostic or clinical reporting frameworks.
Investors and researchers following TXG news will also find periodic financial results, preliminary revenue updates and participation in healthcare and investor conferences. Together, these items provide insight into the company’s product adoption, geographic reach, research impact and engagement with the broader scientific and investment communities. Users interested in 10x Genomics can use this page to review company press releases and related coverage over time.
Summary not available.
10x Genomics, a leader in life sciences, announced its participation in a fireside chat at the BofA Securities 2023 Healthcare Conference on May 10, 2023, at 2:20 p.m. Pacific Time. The event will focus on advancing human health through innovative biological solutions.
Investors can access a live webcast of the chat via the company's website, with an archive available for replay for at least 45 days. 10x Genomics specializes in integrated solutions that include instruments, consumables, and software for biological analysis. The company has a strong presence in top research institutions and pharmaceutical companies, cited in over 4,500 research papers.
10x Genomics (NASDAQ: TXG) announced it will release its first quarter 2023 financial results on May 3, 2023, after market close. A conference call will follow at 1:30 PM PT to discuss the results and future outlook.
The company, a leader in life sciences, provides products for analyzing biological systems, with a significant presence in top global research institutions and pharmaceutical companies. 10x Genomics boasts a portfolio of over 1,750 patents and its products are widely cited in scientific literature.
10x Genomics (Nasdaq: TXG), a leader in life sciences, announced its participation in the 43rd Annual Cowen Healthcare Conference in Boston, Massachusetts, scheduled for March 6, 2023, at 11:10 a.m. Eastern Time. The management team will engage in a fireside chat, which will be accessible via a live webcast on the company’s investors page.
10x Genomics specializes in developing technology to analyze complex biological systems, with a broad patent portfolio and products used by top global research institutions and pharmaceutical companies.
10x Genomics reported Q4 2022 revenue of $156.2 million, up 9% year-over-year, and FY 2022 revenue of $516.4 million, reflecting 5% growth compared to 2021. The increase was driven by strong sales of Chromium X Series instruments, despite a decline in China. New product launches, including the Xenium platform, were highlighted. However, gross margins fell to 76% in Q4 from 81% a year prior, with operating losses widening to $23.1 million. Net loss for Q4 was $17.2 million, slightly improved from $18.4 million in Q4 2021. For 2023, the company forecasts revenue between $580 million and $600 million.
10x Genomics (TXG) announced significant advancements at the 2023 AGBT General Meeting, showcasing its innovative platforms for single-cell analysis and spatial biology.
- Highlighting the scalability of the Chromium Flex platform, demonstrating its capability with data from an 8 million cell experiment.
- New capabilities for Visium CytAssist promise enhanced spatial discovery and a product pipeline including Visium HD.
- The Xenium platform now features a broader menu of customizable panels and the launch of the Xenium Catalyst Program to facilitate researcher access to high-quality data.
These developments reinforce 10x Genomics' leadership in biotechnology.
10x Genomics (TXG) plans to release its financial results for Q4 and full year 2022 on February 15, 2023, after market close. Management will host a conference call at 1:30 PM PT to discuss the results and provide insights on business developments and future outlook. The company's integrated solutions are essential in advancing biological research, with products utilized by top research institutions and pharmaceutical companies. The live webcast will be accessible on their website, with a replay available for at least 45 days.
10x Genomics, Inc. (Nasdaq: TXG), a leader in life sciences, will participate in the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California. Management is set to present on January 9 at 7:30 a.m. PT and participate in a panel on January 10 at 5:15 p.m. PT. The events can be accessed via a live and archived webcast on the company's Investors page. 10x Genomics specializes in products that analyze biological systems, with over 4,100 research citations and a robust patent portfolio.
10x Genomics (Nasdaq: TXG) has announced the commercial launch of the Xenium platform, enabling high-throughput in situ analysis of gene and protein expression at the subcellular level. The platform, which includes a versatile instrument and interactive software, allows researchers to explore complex biological data with high sensitivity. Key features include class-leading speed, broad gene panel compatibility, and intact tissue morphology compatibility. This launch signifies a notable advancement in biological analysis technology, aimed at answering critical research questions in fields like oncology and neurobiology.
10x Genomics (TXG) announced the commercial launch of BEAM (Barcode Enabled Antigen Mapping), a new solution aimed at accelerating antibody and T-cell receptor discovery. Built on the Chromium Single Cell Immune Profiling technology, BEAM allows comprehensive antigen screening, significantly improving therapeutic discovery timelines. The workflow is optimized for efficiency, taking only a week and promising robust data output. This marks the sixth major product launch from 10x Genomics in 2022, demonstrating the strength of its R&D pipeline, with shipping expected to begin in December 2022.